Trevi Therapeutics (TRVI) Scheduled to Post Quarterly Earnings on Tuesday

Trevi Therapeutics (NASDAQ:TRVI) will be releasing its earnings data after the market closes on Tuesday, May 7th. Analysts expect Trevi Therapeutics to post earnings of ($0.09) per share for the quarter.

Trevi Therapeutics (NASDAQ:TRVI) last released its earnings results on Wednesday, March 20th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.02. On average, analysts expect Trevi Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Trevi Therapeutics Stock Down 2.4 %

TRVI stock opened at $2.86 on Thursday. The company has a market cap of $201.43 million, a price-to-earnings ratio of -9.86 and a beta of 0.91. Trevi Therapeutics has a twelve month low of $0.97 and a twelve month high of $4.00. The business has a 50 day moving average price of $3.01 and a two-hundred day moving average price of $2.02.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Trevi Therapeutics in a report on Tuesday, April 9th. Oppenheimer reissued an “outperform” rating and issued a $9.00 price target on shares of Trevi Therapeutics in a report on Thursday, March 21st.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.